- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01707030
Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
As many as 80% of Veterans with the hepatitis C virus (HCV) engage in harmful drinking. This is a major health challenge given that even light and moderate alcohol consumption can worsen the course and consequences of HCV and can be a barrier to receiving antiviral therapy. In response, the VA Uniform Mental Health Services Package has made it a priority that HCV and other ambulatory clinics provide evidence-based mental health services to all Veterans engaging in harmful drinking within two week (but preferably the same day as the clinic visit). The investigators' CREATE partners, the VA Office of Mental Health Services, VA Operations (10N), and the VA Office of Public Health, are strongly committed to achieving this standard throughout the Veterans Health Administration (VHA). However, the cost and organizational challenges to meeting this mandate in HCV clinics are enormous, but may be surmountable through the use of self-directed technology that minimizes demands on scarce staff time.
The primary objective of this study is to implement and evaluate a web-based brief alcohol intervention (BAI) for treating Veterans with HCV and seeking care at two VA HCV clinics - Veterans Affairs Palo Alto Health Care System (VAPAHCS) and San Francisco Veterans Affairs Medical Center (SFVAMC). This study will have three aims: First (Aim 1), the investigators plan to assess patient, provider, and system factors that may impact the initial adoption of this intervention in two VA HCV clinics. These data will result in the development of a protocol for the initial implementation of the web-based BAI at the investigators' two study sites. A secondary aim will involve obtaining patient and provider feedback on an existing web-based BAI (see www.bmi-aft.org, VA Intranet Only) to help inform its redesign for use with this population. Second (Aim 2), the investigators will implement and examine the effectiveness of a web-based BAI in two HCV clinics to reduce alcohol consumption in Veterans with HCV at three- and six-months post-treatment. Third (Aim 3), the investigators will conduct a budget impact analysis to estimate the short-term costs (1-3 years) of adoption and diffusion of the web-based BAI and the trajectory of health care spending for study participants.
This mixed-methods study will utilize qualitative and quantitative methods to achieve its three primary aims. To address aim 1, qualitative interviews will be used to collect data that will inform the initial implementation and re-versioning of a web-based BAI for use in two HCV clinics located at the Palo Alto and San Francisco. To address aim 2, the investigators will use a randomized, hybrid (type 1) design with patient level clinical outcome data and formative evaluation data collected to examine the effectiveness of the web-based BAI. "Hybrid" designs also integrate formative evaluation into experimental designs to identify factors that impact the effectiveness of implementation efforts. Formative evaluation (e.g., site visits, clinic observation, and interviews with staff and patients) will be used to improve the adoption of the web-based BAI at both sites and to provide evidence-based guidance to the investigators' CREATE operational partners for nationwide implementation. To address aim 3, the investigators will conduct a budget impact analysis to estimate the short-term costs (1-3 years) of adoption and diffusion of the web-based BAI and the trajectory of health care spending for study participants. The investigators plan to collect several types of utilization data, including outpatient, inpatient, and pharmacy utilization, and calculate total dollars.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
California
-
Palo Alto, California, Stati Uniti, 94304-1290
- VA Palo Alto Health Care System, Palo Alto, CA
-
San Francisco, California, Stati Uniti, 94121
- San Francisco VA Medical Center, San Francisco, CA
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Must be a US military veteran.
- Over the age of 17 with liver disease.
- Must be receiving care at a VA liver clinic.
Exclusion Criteria:
- Those with no current or historical use of alcohol.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: BAI Arm
Receiving a web-based brief intervention for alcohol problems
|
Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
All patients will be receiving care in a Hepatitis C clinic.
In some cases clinicians may counsel them on alcohol problems.
|
Comparatore attivo: Usual Care
In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
|
All patients will be receiving care in a Hepatitis C clinic.
In some cases clinicians may counsel them on alcohol problems.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in Days of Unhealthy Alcohol Consumption
Lasso di tempo: Baseline, 3 months, and 6 months
|
The number of days on which alcohol was consumed beyond recommended levels in the last 30 days.
|
Baseline, 3 months, and 6 months
|
Change in Drinking Days
Lasso di tempo: Baseline, 3 months, and 6 months
|
The number of days on which alcohol was consumed at any level in the last 30 days.
|
Baseline, 3 months, and 6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in Drinks Per Drinking Day
Lasso di tempo: Baseline, 3 months, and 6 months
|
The number of standard drinks (0.5 ounce ethanol equivalent) consumed on those days that an individual drank in the last 30 days.
|
Baseline, 3 months, and 6 months
|
Change in Symptoms of Psychological Distress (PHQ-9)
Lasso di tempo: Baseline, 3 months, and 6 months
|
Symptoms of psychological distress will be measured using the Patient Health Questionnaire (PHQ-9).
The PHQ-9 provides an assessment of depression severity.
The minimum value is 0 and the maximum value is 27.
Lower scores are better.
The reliability, validity, and clinical utility of the PHQ-9 instrument are well-established.
|
Baseline, 3 months, and 6 months
|
Change in SF-12 Physical Health Composite
Lasso di tempo: Baseline, 3 months, and 6 months
|
The Short Form-12 (SF-12) is a 12-item health survey based on the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) designed to assess two component health status summary scales (physical and mental component summaries) in the general U.S. population .
The SF-12 has demonstrated good internal consistency reliability and construct validity.
This reflects the physical health component of the SF-12.
Scores range from 0-100 and higher scores are better.
|
Baseline, 3 months, and 6 months
|
Change in Additional Care
Lasso di tempo: Baseline and 12 months
|
Total costs in dollars of all VA and non-VA inpatient, outpatient and pharmacy costs.
|
Baseline and 12 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in SF-12 Mental Health Composite
Lasso di tempo: Baseline, 3 months, and 6 months
|
The Short Form-12 (SF-12) is a 12-item health survey based on the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) designed to assess two component health status summary scales (physical and mental component summaries) in the general U.S. population.
The SF-12 has demonstrated good internal consistency reliability and construct validity.
This reflects the mental health component of the SF-12.
Scores range from 0-100 and higher scores are better.
|
Baseline, 3 months, and 6 months
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35(1):22-35. doi: 10.1080/10550887.2016.1100960. Epub 2015 Oct 14.
- Cucciare MA, Timko C. Bridging the gap between medical settings and specialty addiction treatment. Addiction. 2015 Sep;110(9):1417-9. doi: 10.1111/add.12977. No abstract available.
- Cucciare MA, Cheung RC, Rongey C. Treating substance use disorders in patients with hepatitis C. Addiction. 2015 Jul;110(7):1057-9. doi: 10.1111/add.12893. Epub 2015 Mar 27. No abstract available.
- Timko C, Kong C, Vittorio L, Cucciare MA. Screening and brief intervention for unhealthy substance use in patients with chronic medical conditions: a systematic review. J Clin Nurs. 2016 Nov;25(21-22):3131-3143. doi: 10.1111/jocn.13244. Epub 2016 May 3.
- Cucciare MA, Jamison AL, Combs AS, Joshi G, Cheung RC, Rongey C, Huggins J, Humphreys K. Adapting a computer-delivered brief alcohol intervention for veterans with Hepatitis C. Inform Health Soc Care. 2017 Dec;42(4):378-392. doi: 10.1080/17538157.2016.1255628. Epub 2017 Jan 9.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Disordini mentali
- Disturbi indotti chimicamente
- Malattie dell'apparato digerente
- Disturbi correlati all'alcol
- Disturbi Correlati a Sostanze
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie del fegato
- Flaviviridae Infezioni
- Epatite, virale, umana
- Infezioni da enterovirus
- Infezioni da Picornaviridae
- Alcolismo
- Epatite
- Epatite A
- Epatite C
Altri numeri di identificazione dello studio
- CRE 12-009
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Web-Based Brief Alcohol Intervention
-
University of TulsaTerminatoSuicidio, tentatoStati Uniti
-
University of MiamiUnited States Department of DefenseIscrizione su invito
-
Memorial Sloan Kettering Cancer CenterCompletatoCancro alla prostataStati Uniti
-
University of MinhoCompletatoObesità pediatricaPortogallo
-
Centre Hospitalier Universitaire de NīmesCompletatoConfronto di 2 test per diagnosticare le disfunzioni cognitive nella malattia da alcol (MoCA/BEARNI)Disturbo da uso di alcolFrancia
-
Universitätsklinikum Hamburg-EppendorfHeinrich-Heine University, Duesseldorf; University of Cologne; University Medical... e altri collaboratoriCompletatoSclerosi multipla, recidivante-remittenteGermania
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)Attivo, non reclutanteOttimizzazione della sorveglianza attiva nel carcinoma prostatico a basso rischio: uno studio pilotaCancro alla prostataStati Uniti
-
Boston Children's HospitalCompletatoDiabete mellito, tipo 1Stati Uniti
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completato
-
Talaria, IncNational Cancer Institute (NCI)CompletatoCancro al senoStati Uniti